Search

Your search keyword '"Fouillard, Loic"' showing total 43 results
Start Over Author "Fouillard, Loic"
43 results on '"Fouillard, Loic"'

1. Tandem Autologous Stem Cell Transplantation Improves Outcomes in Newly Diagnosed Multiple Myeloma with Extramedullary Disease and High-Risk Cytogenetics: A Study from the Chronic Malignancies Working Party of the European Society for Blood and Marrow Transplantation

Author

Gagelmann, Nico, Eikema, Diderik-Jan, Koster, Linda, Caillot, Denis, Pioltelli, Pietro, Lleonart, Juan Bargay, Reményi, Péter, Blaise, Didier, Schaap, Nicolaas, Trneny, Marek, Passweg, Jakob, Porras, Rocio Parody, Cahn, Jean Yves, Musso, Maurizio, Poiré, Xavier, Fenk, Roland, Itälä-Remes, Maija, Pavone, Vincenzo, Fouillard, Loic, Maertens, Johan, Bron, Dominique, Pouli, Anastasia, Schroyens, Wilfried, Schönland, Stefan, Garderet, Laurent, Yakoub-Agha, Ibrahim, and Kröger, Nicolaus

Published
2019
Full Text
View/download PDF

4. Randomized, phase 2 trial of low-dose cytarabine with or without volasertib in AML patients not suitable for induction therapy

Author

Döhner, Hartmut, Lübbert, Michael, Fiedler, Walter, Fouillard, Loic, Haaland, Alf, Brandwein, Joseph M., Lepretre, Stephane, Reman, Oumedaly, Turlure, Pascal, Ottmann, Oliver G., Müller-Tidow, Carsten, Krämer, Alwin, Raffoux, Emmanuel, Döhner, Konstanze, Schlenk, Richard F., Voss, Florian, Taube, Tillmann, Fritsch, Holger, and Maertens, Johan

Published
2014
Full Text
View/download PDF

5. Efficacy, safety and feasibility of treatment of chronic HCV infection with directly acting agents in hematopoietic stem cell transplant recipients – Study of infectious diseases working party of EBMT

Author

Mikulska, Malgorzata, primary, Knelange, Nina, additional, Nicolini, Laura Ambra, additional, Tridello, Gloria, additional, Santarone, Stella, additional, Di Bartolomeo, Paolo, additional, de la Camara, Rafael, additional, Cuéllar, Clara, additional, Velardi, Andrea, additional, Perruccio, Katia, additional, Ljungman, Per, additional, Zaucha, Jan, additional, Piekarska, Agnieszka, additional, Basak, Grzegorz, additional, Karakulska-Prystupiuk, Ewa, additional, Angelucci, Emanuele, additional, Ciceri, Fabio, additional, Lupo-Stanghellini, Maria Teresa, additional, Fouillard, Loic, additional, García-Cadenas, Irene, additional, Menconi, Mariacristina, additional, Blau, Igor Wolfgang, additional, Nassi, Luca, additional, Cesaro, Simone, additional, and Styczynski, Jan, additional

Published
2022
Full Text
View/download PDF

8. Reactive Hemophagocytic Syndrome after Hematopoietic Stem Cell Transplantation: A Multicenter Retrospective Study on Behalf of the Francophone Society of Stem Cell Transplantation and Cellular Therapy (SFGM-TC)

Author

Simonetta, Federico, primary, Labussière-Wallet, Hélène, additional, Machaczka, Maciej J, additional, Sicre de Fontbrune, Flore, additional, Medinger, Michael, additional, Chantepie, Sylvain, additional, Marchand, Tony, additional, Masouridi-Levrat, Stavroula, additional, Rubio, Marie-Thérèse, additional, Reman, Oumedaly, additional, Dhedin, Nathalie, additional, Fouillard, Loic, additional, Lambotte, Olivier, additional, Galicier, Lionel, additional, Coppo, Paul, additional, Passweg, Jakob, additional, Yakoub-Agha, Ibrahim, additional, Peffault De Latour, Regis, additional, and Chalandon, Yves, additional

Published
2016
Full Text
View/download PDF

9. Performance of serum biomarkers for the early detection of invasive aspergillosis in febrile, neutropenic patients: a multi-state model

Author

Schwarzinger , Michaël, Sagaon-Teyssier , Luis, Cabaret , Odile, Bretagne , Stéphane, Cordonnier , Catherine, Renseigné , Non, Pautas , Cécile, Maury , Sébastien, Hicheri , Yosr, Botterel , Françoise, Foulet , Francoise, Vekhoff , Anne, Chaoui , Driss, Cornet , Muriel, Agnamey , Patrice, Farhat , Hassan, Castaigne , Sylvie, Eloy , Odile, Suarez , Felipe, Buzyn , Agnès, Delarue , Richard, Challier , Svetlana, Dhedin , Nathalie, Aljijakli , Ahmad, Delabesse , Emmanuelle, Datry , Annick, Isnard , Françoise, Fouillard , Loic, Poirot , Jean-Yves, Meliani , Leila, Adès , Lionel, Bouges-Michel , Claire, Deniau , Michèle, Kuhnowski , Frédérique, Dreyfus , François, Paugam , André, Baixench , Marie-Thérèse, Leclercq , Roland, Reman , Oumady, Duhamel , Chantal, Bourrhis , Jean-Henri, Chehata , Sami, Chachati , Isabelle, Foissaud , Vincent, Macnab , Christine, Tilly , Hervé, Leprêtre , Stéphane, Gray , Christian, Raffoux , Emmanuel, Lacroix , Claire, Goldhaber-Fiebert , Jeremy D, Bendavid , Eran, Farley , Brandon J, Modèles et méthodes de l'évaluation thérapeutique des maladies chroniques (U738 / UMR_S738), Institut National de la Santé et de la Recherche Médicale (INSERM)-Université Paris Diderot - Paris 7 (UPD7), Programme ATIP - Avenir, Institut National de la Santé et de la Recherche Médicale (INSERM)-Centre National de la Recherche Scientifique (CNRS), Sciences Economiques et Sociales de la Santé & Traitement de l'Information Médicale (SESSTIM - U912 INSERM - Aix Marseille Univ - IRD), Institut de Recherche pour le Développement (IRD)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Aix Marseille Université (AMU), CHU Henri Mondor, Mycologie moléculaire, Institut Pasteur [Paris]-Centre National de la Recherche Scientifique (CNRS), Centre National de Référence Mycologie et Antifongiques-Mycologie Moléculaire (CNRMA), Institut Pasteur [Paris], Université Paris-Est Créteil Val-de-Marne - Paris 12 (UPEC UP12), Service d'hématologie clinique, Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Hôpital Henri Mondor-Université Paris-Est Créteil Val-de-Marne - Paris 12 (UPEC UP12), Université Paris Diderot - Paris 7 (UPD7)-Institut National de la Santé et de la Recherche Médicale (INSERM), Institut de Recherche pour le Développement (IRD)-Aix Marseille Université (AMU)-Institut National de la Santé et de la Recherche Médicale (INSERM), CHU Henri Mondor [Créteil], Institut Pasteur [Paris] (IP)-Centre National de la Recherche Scientifique (CNRS), Institut Pasteur [Paris] (IP), Sciences Economiques et Sociales de la Santé & Traitement de l'Information Médicale ( SESSTIM - U912 INSERM - AMU - IRD ), Institut de Recherche pour le Développement ( IRD ) -Aix Marseille Université ( AMU ) -Institut National de la Santé et de la Recherche Médicale ( INSERM ), Institut Pasteur [Paris]-Centre National de la Recherche Scientifique ( CNRS ), Centre National de Référence Mycologie et Antifongiques-Mycologie Moléculaire ( CNRMA ), Assistance publique - Hôpitaux de Paris (AP-HP)-Hôpital Henri Mondor-Université Paris-Est Créteil Val-de-Marne - Paris 12 ( UPEC UP12 ), Laboratoire de Parasitologie-Mycologie, CHU Saint-Antoine [APHP], Thérapeutique Recombinante Expérimentale ( TIMC-IMAG-THEREX ), Techniques de l'Ingénierie Médicale et de la Complexité - Informatique, Mathématiques et Applications [Grenoble] ( TIMC-IMAG ), Université Joseph Fourier - Grenoble 1 ( UJF ) -Institut polytechnique de Grenoble - Grenoble Institute of Technology ( Grenoble INP ) -IMAG-Centre National de la Recherche Scientifique ( CNRS ) -Université Grenoble Alpes ( UGA ) -Université Joseph Fourier - Grenoble 1 ( UJF ) -Institut polytechnique de Grenoble - Grenoble Institute of Technology ( Grenoble INP ) -IMAG-Centre National de la Recherche Scientifique ( CNRS ) -Université Grenoble Alpes ( UGA ), Service des maladies infectieuses et tropicales [Rouen], CHU Rouen-Université de Rouen Normandie ( UNIROUEN ), Normandie Université ( NU ) -Normandie Université ( NU ), Laboratoire d'hématologie ( ERL 8254 ), Imagine - Institut des maladies génétiques ( IMAGINE - U1163 ), Université Paris Descartes - Paris 5 ( UPD5 ) -Institut National de la Santé et de la Recherche Médicale ( INSERM ) -Centre National de la Recherche Scientifique ( CNRS ) -Université Paris Descartes - Paris 5 ( UPD5 ) -Institut National de la Santé et de la Recherche Médicale ( INSERM ) -Centre National de la Recherche Scientifique ( CNRS ), Centre de Référence Déficits Immunitaires Héréditaires ( CEREDIH ), Assistance publique - Hôpitaux de Paris (AP-HP)-CHU Necker - Enfants Malades [AP-HP], Institut Cochin ( UMR_S567 / UMR 8104 ), Université Paris Descartes - Paris 5 ( UPD5 ) -Institut National de la Santé et de la Recherche Médicale ( INSERM ) -Centre National de la Recherche Scientifique ( CNRS ), Service d'immuno-hématologie pédiatrique [CHU Necker], Service d'hématologie clinique et de thérapie cellulaire [CHU Saint-Antoine], Assistance publique - Hôpitaux de Paris (AP-HP)-CHU Saint-Antoine [APHP], Service d'hématologie clinique [Avicenne], Université Paris 13 ( UP13 ) -Assistance publique - Hôpitaux de Paris (AP-HP)-Hôpital Avicenne, Service d'hématologie, Assistance publique - Hôpitaux de Paris (AP-HP)-CHU Cochin [AP-HP], CHU Cochin [AP-HP], Interactions hôte et microorganismes des épithéliums, Université de Caen Normandie ( UNICAEN ), Laboratoire de biologie médicale, Service de Santé des Armées-Hôpital d'instruction des Armées Percy, Service de Santé des Armées, Service d'oncologie, CRLCC Henri Becquerel, Groupe d'étude des proliférations lymphoïdes ( GPL ), Université de Rouen Normandie ( UNIROUEN ), Normandie Université ( NU ) -Normandie Université ( NU ) -Institut National de la Santé et de la Recherche Médicale ( INSERM ), Service d'hématologie biologique, Assistance publique - Hôpitaux de Paris (AP-HP)-Groupe Hospitalier Saint Louis - Lariboisière - Fernand Widal [Paris], Ingénierie des Matériaux Polymères - Laboratoire des Matériaux Macromoléculaires ( IMP-LMM ), Université Claude Bernard Lyon 1 ( UCBL ), Université de Lyon-Université de Lyon-Institut National des Sciences Appliquées de Lyon ( INSA Lyon ), Université de Lyon-Institut National des Sciences Appliquées ( INSA ) -Institut National des Sciences Appliquées ( INSA ) -Université Jean Monnet [Saint-Étienne] ( UJM ) -Centre National de la Recherche Scientifique ( CNRS ), and Centre National de la Recherche Scientifique (CNRS)-Institut Pasteur [Paris]

Subjects
Oncology, Male, Myeloid, Antifungal Agents, beta-Glucans, Epidemiology, lcsh:Medicine, Fevers, Aspergillosis, Hematologic Cancers and Related Disorders, Mannans, chemistry.chemical_compound, 0302 clinical medicine, [SDV.MHEP.MI]Life Sciences [q-bio]/Human health and pathology/Infectious diseases, 030212 general & internal medicine, Prospective Studies, Chemotherapy-Induced Febrile Neutropenia, lcsh:Science, Prospective cohort study, DNA, Fungal, [ SDV.MP.MYC ] Life Sciences [q-bio]/Microbiology and Parasitology/Mycology, Randomized Controlled Trials as Topic, Invasive Pulmonary Aspergillosis, 0303 health sciences, Multidisciplinary, Fungal genetics, Blood Screening, Fungal Diseases, Hematology, Middle Aged, Markov Chains, 3. Good health, Leukemia, Myeloid, Acute, medicine.anatomical_structure, Infectious Diseases, Blood, Biomarker (medicine), Medicine, Female, Research Article, Adult, medicine.medical_specialty, Antigens, Fungal, Neutropenia, Genes, Fungal, Antineoplastic Agents, Biology, Real-Time Polymerase Chain Reaction, Models, Biological, 03 medical and health sciences, Galactomannan, Internal medicine, Leukemias, medicine, Humans, Aged, Antifungals, Acute myeloid leukemia, 030306 microbiology, lcsh:R, Cancers and Neoplasms, Galactose, Fungal Polysaccharides, medicine.disease, Diagnostic medicine, Biomarker Epidemiology, Early Diagnosis, chemistry, Immunology, lcsh:Q, Biomarkers
Abstract

International audience; BACKGROUND: The performance of serum biomarkers for the early detection of invasive aspergillosis expectedly depends on the timing of test results relative to the empirical administration of antifungal therapy during neutropenia, although a dynamic evaluation framework is lacking. METHODS: We developed a multi-state model describing simultaneously the likelihood of empirical antifungal therapy and the risk of invasive aspergillosis during neutropenia. We evaluated whether the first positive test result with a biomarker is an independent predictor of invasive aspergillosis when both diagnostic information used to treat and risk factors of developing invasive aspergillosis are taken into account over time. We applied the multi-state model to a homogeneous cohort of 185 high-risk patients with acute myeloid leukemia. Patients were prospectively screened for galactomannan antigenemia twice a week for immediate treatment decision; 2,214 serum samples were collected on the same days and blindly assessed for (1->3)- β-D-glucan antigenemia and a quantitative PCR assay targeting a mitochondrial locus. RESULTS: The usual evaluation framework of biomarker performance was unable to distinguish clinical benefits of β-glucan or PCR assays. The multi-state model evidenced that the risk of invasive aspergillosis is a complex time function of neutropenia duration and risk management. The quantitative PCR assay accelerated the early detection of invasive aspergillosis (P = .010), independently of other diagnostic information used to treat, while β-glucan assay did not (P = .53). CONCLUSIONS: The performance of serum biomarkers for the early detection of invasive aspergillosis is better apprehended by the evaluation of time-varying predictors in a multi-state model. Our results provide strong rationale for prospective studies testing a preemptive antifungal therapy, guided by clinical, radiological, and bi-weekly blood screening with galactomannan antigenemia and a standardized quantitative PCR assay.

Published
2013

10. Clinical-grade production of human mesenchymal stromal cells: occurrence of aneuploidy without transformation

Author

Tarte, Karin, Gaillard, Julien, Lataillade, Jean-Jacques, Fouillard, Loic, Becker, Martine, Mossafa, Hossein, Tchirkov, Andrei, Rouard, Hélène, Henry, Catherine, Splingard, Marie, Dulong, Joelle, Monnier, Delphine, Gourmelon, Patrick, Gorin, Norbert-Claude, Sensebé, Luc, and on behalf of Société Française de Greffe de Moelle et Thérapie Cellulaire

Published
2010
Full Text
View/download PDF

12. Innovative Cell Therapy in the Treatment of Serious Adverse Events Related to Both Chemo-Radiotherapy Protocol and Acute Myeloid Leukemia Syndrome: The Infusion of Mesenchymal Stem Cells Post-Treatment Reduces Hematopoietic Toxicity and Promotes Hematopoietic Reconstitution

Author

Fouillard, Loic, primary, Francois, Sabine, additional, Bouchet, Sandrine, additional, Bensidhoum, Morad, additional, Elm’selmi, Abdelatif, additional, and Chapel, Alain, additional

Published
2014
Full Text
View/download PDF

14. Phase I/II Study of Volasertib (BI 6727), an Intravenous Polo-Like Kinase (Plk) Inhibitor, in Patients with Acute Myeloid Leukemia (AML): Results From the Randomized Phase II Part for Volasertib in Combination with Low-Dose Cytarabine (LDAC) Versus LDAC Monotherapy in Patients with Previously Untreated AML Ineligible for Intensive Treatment

Author

Maertens, Johan, primary, Lübbert, Michael, additional, Fiedler, Walter, additional, Fouillard, Loic, additional, Haaland, Alf, additional, Brandwein, Joseph M., additional, Lepretre, Stéphane, additional, Reman, Oumédaly, additional, Turlure, Pascal, additional, Bug, Gesine, additional, Müller-Tidow, Carsten, additional, Krämer, Alwin, additional, Voss, Florian, additional, Taube, Tillmann, additional, Fritsch, Holger, additional, and Döhner, Hartmut, additional

Published
2012
Full Text
View/download PDF

15. Autologous stem cell transplantation for systemic lupus erythematosus.

Author

Jayne, David R.W.David, Passweg, Jacob, Marmont, Alberto, Farge, Dominique, Zhao, Xiaowu, Arnold, Robert D, Hiepe, Falk, Lisukov, Igor, Musso, Maurizio, Ou-Yang, Jian, Marsh, Judith, Wulffraat, Nicolas M, Besalduch, Juan, Bingham, Sarah J, Emery, Paul, Brune, Mats, Fassas, Athanasios, Faulkner, Lawrence, Ferster, Alina, Fiehn, Christoph, Fouillard, Loic, Geromin, Antonella, Greinix, Hildegard, Rabusin, Marco, Saccardi, Riccardo, Schneider, Peter, Zintl, F, Gratwohl, Alois, Tyndall, Alan, European Group for Blood and Marrow Transplantation, European League Against Rheumatism Registry, Jayne, David R.W.David, Passweg, Jacob, Marmont, Alberto, Farge, Dominique, Zhao, Xiaowu, Arnold, Robert D, Hiepe, Falk, Lisukov, Igor, Musso, Maurizio, Ou-Yang, Jian, Marsh, Judith, Wulffraat, Nicolas M, Besalduch, Juan, Bingham, Sarah J, Emery, Paul, Brune, Mats, Fassas, Athanasios, Faulkner, Lawrence, Ferster, Alina, Fiehn, Christoph, Fouillard, Loic, Geromin, Antonella, Greinix, Hildegard, Rabusin, Marco, Saccardi, Riccardo, Schneider, Peter, Zintl, F, Gratwohl, Alois, Tyndall, Alan, European Group for Blood and Marrow Transplantation, and European League Against Rheumatism Registry

Abstract

Systemic lupus erythematosus (SLE) is responsive to treatment with immunosuppressives and steroids, but often pursues a relapsing or refractory course resulting in increasing incapacity and reduced survival. Autologous stem cell transplantation (ASCT) following immunoablative chemotherapy is a newer therapy for autoimmune disease of potential use in severe SLE. A retrospective registry survey was carried out by the European Blood and Marrow Transplant and European League Against Rheumatism (EBMT/EULAR) registry. Data was collected from 53 patients with SLE treated by ASCT in 23 centres. Disease duration before ASCT was 59 (2-155) months (median, range), 44 (83%) were female, and median age was 29 (9-52) years. At the time of ASCT a median of seven American College of Rheumatology (ACR) diagnostic criteria for SLE were present (range 2-10) and 33 (62%) had nephritis. Peripheral blood stem cells were mobilized with cyclophosphamide and granulocyte colony stimulating factor in 93% of cases. Ex vivo CD34 stem cell selection was performed in 42% of patients. Conditioning regimens employed cyclophosphamide in 84%, anti-thymocyte globulin in 76% and lymphoid irradiation in 22%. The mean duration of follow-up after ASCT was 26 (0-78) months. Remission of disease activity (SLEDAI < 3) was seen in 33/50 (66%; 95%CI 52-80) evaluable patients by six months, of which 10/31 (32%; 95%CI 15-50) subsequently relapsed after six (3-40) months. Relapse was associated with negative anti-double stranded DNA (anti-dsDNA) antibodies before ASCT (P = 0.007). There were 12 deaths after 1.5 (0-48) months, of which seven (12%; 95%CI 3-21) were related to the procedure. Mortality was associated with a longer disease course before ASCT (P = 0.036). In conclusion, this registry study demonstrates the efficacy of ASCT for remission induction of refractory SLE, although mortality appeared high. The safety of this procedure is likely to be improved by patient selection and choice of conditioning reg, Comparative Study, Journal Article, Research Support, Non-U.S. Gov't, SCOPUS: ar.j, info:eu-repo/semantics/published

Published
2004

16. Disease Status Is the Major Prognosis Factor for Allogenic Transplantation Outcome for Hodgkin Lymphoma: a Retrospective Study From the French Society of Bone Marrow Graft Transplantation and Cellular Therapy (SFGM-TC)

Author

Marcais, Ambroise, primary, Bilger, Karin, additional, Porcher, Raphael, additional, Robin, Marie, additional, Mohty, Mohamad, additional, Michalet, Mauricette, additional, Blaise, Didier, additional, Vigouroux, Stephane, additional, Bordigoni, Pierre, additional, Ceballos, Patrice, additional, Deconinck, Eric, additional, Dehdin, Nathalie, additional, Rio, Bernard, additional, Bay, Jacques-Olivier, additional, Pautas, Cécile, additional, Garban, Frederic, additional, Ifrah, Norbert, additional, Suarez, Felipe, additional, Guillerm, Gaelle, additional, Contentin, Nathalie, additional, Bourhis, Jean-Henri, additional, Bernard, Marc, additional, Cornillon, Jérôme, additional, Huynh, Anne, additional, Agha, Ibrahim yakoub, additional, Sirvent, Anne, additional, Fouillard, Loic, additional, and Buzyn, Agnes, additional

Published
2010
Full Text
View/download PDF

17. Safety and Efficacy of FLAMSA Regimen Followed by Allogeneic Hematopoietic Stem Cell Transplantation From Related and Unrelated Donors in High Risk Acute Leukemia and MDS Patients: A Study From the Societe Française De Greffe De Moelle Et De Therapie Cellulaire (SFGM-TC) Registry.

Author

Cannas, Giovanna, primary, Huynh, Anne, additional, Morisset, Stéphane, additional, Sobh, Mohamad, additional, Raus, Nicole, additional, Garban, Frederic, additional, Cordonnier, Catherine, additional, Bay, Jacques-Olivier, additional, Cornillon, Jérôme, additional, Buzyn, Agnes, additional, Yakoub-Agha, Ibrahim, additional, Faucher, Catherine, additional, Francois, Sylvie, additional, Bordigoni, Pierre, additional, Fegueux, Nathalie, additional, Fouillard, Loic, additional, Robin, Marie, additional, Deconinck, Eric, additional, Reman, Oumédaly, additional, Dhedin, Nathalie, additional, Revel, Thierry De, additional, Lioure, Bruno, additional, Milpied, Noel, additional, Mohty, Mohamad, additional, and Michallet, Mauricette, additional

Published
2009
Full Text
View/download PDF

18. Higher Incidence of Relapse With Peripheral Blood Rather Than Marrow As a Source of Stem Cells in Adults With Acute Myelocytic Leukemia Autografted During the First Remission

Author

Gorin, Norbert-Claude, primary, Labopin, Myriam, additional, Blaise, Didier, additional, Reiffers, Josy, additional, Meloni, Giovanna, additional, Michallet, Mauricette, additional, de Witte, Theo, additional, Attal, Michel, additional, Rio, Bernard, additional, Witz, Francois, additional, Fouillard, Loic, additional, Willemze, Roel, additional, and Rocha, Vanderson, additional

Published
2009
Full Text
View/download PDF

19. Double Cord Blood Cell (CBC) Hematopoietic Stem Cell Transplantation after Standard or Reduced Intensity Conditioning: Report of the SFGMTC Registry.

Author

Michallet, Mauricette, primary, Le, Quoc Hung, primary, Robin, Marie, primary, Fegueux, Nathalie, primary, Furst, Sabine, primary, Mohty, Mohamad, primary, Deconinck, Eric, primary, Fouillard, Loic, primary, Bordigoni, Pierre, primary, Rio, Bernard, primary, Sirvent, Anne, primary, Renaud, Marc, primary, Dhedin, Nathalie, primary, Tabrizi, Reza, primary, Maury, Sebastien, primary, Sobh, Mohamad, primary, Raus, Nicole, primary, Garnier, Federico, primary, Balere, Marie-Lorraine, primary, Rocha, Vanderson, primary, Blaise, Didier, primary, and Labussiere, Helene, primary

Published
2008
Full Text
View/download PDF

22. Allogeneic Myelo-Ablative Stem Cell Transplant (SCT) as Salvage Therapy of Reduced-Intensity Conditioned (RIC) SCT: Toxicity and Outcome.

Author

Cordonnier, Catherine, primary, Hamladji, Rose-marie, primary, Gratwohl, Alois, primary, Ljungman, Per, primary, Martino, Rodrigo, primary, Bordigoni, Pierre, primary, François, Sylvie, primary, Deconninck, Eric, primary, Buzyn, Agnes, primary, Bay, Jacques-Olivier, primary, Fouillard, Loic, primary, and Kuentz, Mathieu, primary

Published
2005
Full Text
View/download PDF

23. Stro-1 Positive and Stro-1 Negative Human Mesenchymal Stem Cells Express Different Levels of Immunosuppression.

Author

Francois, Sabine, primary, Zhang, Yizhuo, primary, Bensidhoum, Morad, primary, Mazurier, Christelle, primary, Nasef, Aisha, primary, Bouchet, Sandrine, primary, Mathieu, Noelle, primary, Gorin, Norbert-Claude, primary, Lopez, Manuel, primary, Bourgeade, Michel, primary, Thierry, Dominique, primary, Chapel, Alain, primary, and Fouillard, Loic, primary

Published
2005
Full Text
View/download PDF

24. Inhibition of T Lymphocyte (TL) Proliferation by Mesenchymal Stem Cells (MSCs): Role of Cell Contact between MSCs and TL, Role of MSCs Dose Effect, and Role of Soluble Factors and Adhesion Molecules Expressed by MSCs.

Author

Nasef, Aisha, primary, Chapel, Alain, primary, Benshidom, Morad, primary, Zang, Yizhuo, primary, Mazurier, Christelle, primary, Bouchet, Sandrine, primary, Lopez, Manuel, primary, Gorin, Norbert Claude, primary, Thierry, Dominique, primary, and Fouillard, Loic, primary

Published
2004
Full Text
View/download PDF

27. Mesenchymal stem cells home to injured tissues when co-infused with hematopoietic cells to treat a radiation-induced multi-organ failure syndrome

Author

Chapel, Alain, primary, Bertho, Jean Marc, additional, Bensidhoum, Morad, additional, Fouillard, Loic, additional, Young, Randell G., additional, Frick, Johanna, additional, Demarquay, Christelle, additional, Cuvelier, Fr�d�rique, additional, Mathieu, Emilie, additional, Trompier, Fran�ois, additional, Dudoignon, Nicolas, additional, Germain, Claire, additional, Mazurier, Christelle, additional, Aigueperse, Jocelyne, additional, Borneman, Jade, additional, Gorin, Norbert Claude, additional, Gourmelon, Patrick, additional, and Thierry, Dominique, additional

Published
2003
Full Text
View/download PDF

31. Innovative Cell Therapy in the Treatment of Serious Adverse Events Related to Both Chemo-Radiotherapy Protocol and Acute Myeloid Leukemia Syndrome: The Infusion of Mesenchymal Stem Cells Post-Treatment Reduces Hematopoietic Toxicity and Promotes Hematopoietic Reconstitution

Author

Fouillard, Loic

Abstract

Bone marrow stroma is damaged by chemotherapy and irradiation protocol. Bone marrow microenvironment supports haematopoiesis and comprises Mesenchymal Stem Cells (MSCs). Coinfusion of MSCs with hematopoietic stem cells (HSC) improves engraftment and accelerates haematopoietic recovery. Stroma-derived factor-1 (SDF-1) is a chemotactic factor which plays a crucial role in stem cell transplantation by enhancing the ability of HSC to engraft. In this study expression of SDF-1 in bone marrow MSCs and the level of Colony Forming Unit Fibroblast (CFU-F) were evaluated in 8 patients with Acute Myeloid leukemia (AML). Evaluation was done at diagnosis and after induction/consolidation chemotherapy before the onset of haematopoietic stem cell transplantation (HSCT). CFU-F frequency increases from diagnosis to remission. Nevertheless level of stromal derived factor-1 (SDF-1) transcripts in bone marrow MSCs of patients with AML stays low. Considering the role of SDF-1 in the homing of HSC, the consequences of SDF-1 deficiency observed in this study might be deleterious on the engraftment after HSCT and haematopoietic recovery. The whole result of this clinical study is an argument for MSC infusion to restore a normal level of SDF1 in the bone marrow microenvironment that could reduce hematopoietic toxicity of chemotherapy and improve HSC engraftment after HSCT.

Published
2013

32. Isolated bone marrow Hodgkin lymphoma in a human immunodeficiency virus-negative patient: a second case.

Author

Cacoub, Léa, Touati, Samia, Yver, Matthieu, Frayfer, Jamile, Abarah, Wajed, Andre-Kerneis, Elisabeth, Branch, Donald R., Forceville, Xavier, and Fouillard, Loic

Subjects
HODGKIN'S disease, EPSTEIN-Barr virus diseases, CD20 antigen, ERYTHROCYTES, BONE marrow examination, AFRICAN American men, DIAGNOSIS, DISEASES
Abstract

The article presents a case study of a 50-year-old HIV-negative African American male who went to the emergency because he was feeling unwell. Blood tests revealed a pancytopenia and a subsequent bone marrow aspiration was performed. The article discusses a diagnosis of isolated bone marrow Hodgkin lymphoma (HL), the presence of the CD antigens in his red blood cells (RBCs), and the impacts of infection with the Epstein–Barr virus (EBV) and CD20 negativity on the treatment's effectiveness.

Published
2014
Full Text
View/download PDF

33. Homing of in vitro expanded Stro-1-or Stro-1+human mesenchymal stem cells into the NOD/SCID mouse and their role in supporting human CD34 cell engraftment

Author

Bensidhoum, Morad, Chapel, Alain, Francois, Sabine, Demarquay, Christelle, Mazurier, Christelle, Fouillard, Loic, Bouchet, Sandrine, Bertho, Jean Marc, Gourmelon, Patrick, Aigueperse, Jocelyne, Charbord, Pierre, Gorin, Norbert Claude, Thierry, Dominique, and Lopez, Manuel

Abstract

The Stro-1 antigen potentially defines a mesenchymal stem cell (MSC) progenitor subset. We here report on the role of human ex vivo-expanded selected Stro-1+or Stro-1-MSC subsets on the engraftment of human CD34+cord blood cells in the nonobese diabetic/severe combined immunodeficiency (NOD/SCID) mouse model. The data show that cotransplantation of expanded Stro-1-cells with CD34+cells resulted in a significant increase of human CD45, CD34, CD19, and CD11b cells detected in blood or in bone marrow (BM) and spleen as compared with the infusion of CD34+cells alone. Infusion into mice of expanded Stro-1+and Stro-1-cells (without CD34+cells) showed that the numbers of Stro-1+-derived (as assessed by DNA analysis of human β-globinwith quantitative polymerase chain reaction [PCR]) were higher than Stro-1--derived cells in spleen, muscles, BM, and kidneys, while more Stro-1--derived than Stro-1+-derived cells were found in lungs. The transduction of expanded Stro-1+cells with an enhanced green fluorescent protein (eGFP) gene did not modify their cytokine release and their homing in NOD/SCID mouse tissues. The difference between the hematopoietic support and the homing capabilities of expanded Stro-1+and Stro-1-cells may be of importance for clinical therapeutic applications: Stro-1+cells may rather be used for gene delivery in tissues while Stro-1-cells may rather be used to support hematopoietic engraftment. (Blood. 2004;103:3313-3319)

Published
2004
Full Text
View/download PDF

34. Clonal T Cell Large Granular Lymphocyte Leukaemia of Recipient Origin after Related Mismatched Allogeneic Haematopoietic Stem Cell Transplantation for Acute Myeloid Leukaemia as a Possible Consequence of Anti-Thymocyte Globulin in Conditioning Regimen

Author

Fouillard, Loïc, Marzac, Christophe, Lagrange, Monique, Huguet-Jacquot, Stéphanie, Fabiani, Betina, Davi, Frederic, Mazurier, Christelle, Soreau, Elisabeth, Laporte, jean-Philippe, Isnard, Francoise, Gorin, norbert-Claude, and Bories, Dominique

Published
2008
Full Text
View/download PDF

36. Retrospective Comparison of Using or Not Using Donor Lymphocyte Transfusion in the Treatment of Hematological Relapse after Allogeneic Stem Cell Transplantation in 489 Adults with Acute Myeloid Leukemia.

Author

Schmid, Christoph, Labopin, Myriam, Finke, Juergen, Ehninger, Gerhard, Ringden, Olle, Niederwieser, Dietger, Sakellari, Ioanna, Urbano-Ispizua, Alvaro, Ruutu, Tapani, Gurman, Gunham, Clarke, Richard E., Gorin, Norbert, Polge, Emmanuelle, Fouillard, Loic, Frassoni, Francesco, and Kolb, Hans-Jochem

Published
2004
Full Text
View/download PDF

37. Impact of cytogenetics on outcome after stem-cell transplantation in multiple myeloma with extramedullary disease: an analysis of the CMWP-EBMT

Author

Gagelmann, Nico, Eikema, Diderik-Jan, Koster, Linda, Caillot, Denis, Pioltelli, Pietro, Bargay Lleonart, Juan, Remenyi, Peter, Didier Blaise, Schaap, Nicolaas, Trneny, Marek, Passweg, Jakob, Parody Porras, Rocio, Cahn, Jean Yves, Musso, Maurizio, Poire, Xavier, Kobbe, Guido, Itala-Remes, Maija, Pavone, Vincenzo, Fouillard, Loic, Schoemans, Helene, Bron, Dominique, Pouli, Anastasia, Schroyens, Wilfried, Garderet, Laurent, and Kroeger, Nicolaus

38. Preparation and Successful Engraftment of Purified CD34+ Bone Marrow Progenitor Cells in Patients With Non-Hodgkin's Lymphoma

Author

Gorin, Norbert-Claude, Lopez, Manuel, Laporte, Jean-Philippe, Quittet, Philippe, Lesage, Sylvie, Lemoine, François, Berenson, Ronald J., Isnard, Françoise, Grande, Mario, Stachowiak, Jerzy, Labopin, Myriam, Fouillard, Loic, Morel, Pierre, Jouet, Jean-Pierre, Noël-Walter, Marie-Pierre, Detourmignies, Laurence, Aoudjhane, Malek, Bauters, Francis, Najman, Albert, and Douay, Luc

Published
1995
Full Text
View/download PDF

40. Pityriasis Rubra Pilaris-Like Reaction Induced by a Tyrosine Kinase Inhibitor, the Ponatinib.

Author

Mongereau M, Hillion B, Fouillard L, Boivin JF, and Gaudron S

Subjects
Aged, Antineoplastic Agents adverse effects, Drug Eruptions etiology, Drug Eruptions pathology, Humans, Leukemia, Myelogenous, Chronic, BCR-ABL Positive drug therapy, Pityriasis Rubra Pilaris pathology, Imidazoles adverse effects, Pityriasis Rubra Pilaris chemically induced, Protein Kinase Inhibitors adverse effects, Pyridazines adverse effects
Abstract

Competing Interests: The authors declare no conflicts of interest.

Published
2021
Full Text
View/download PDF

41. Results of syngeneic hematopoietic stem cell transplantation for acute leukemia: risk factors for outcomes of adults transplanted in first complete remission.

Author

Fouillard L, Labopin M, Gratwohl A, Gluckman E, Frassoni F, Beelen DW, Willemze R, Montserrat E, Blaise D, Atienza AI, Sierra J, Santos M, Gorin NC, and Rocha V

Subjects
Adolescent, Adult, Aged, Antineoplastic Agents therapeutic use, Diseases in Twins, Female, Graft vs Host Disease, Humans, Male, Middle Aged, Recurrence, Remission Induction, Risk Factors, Treatment Outcome, Hematopoietic Stem Cell Transplantation methods, Leukemia, Myeloid, Acute drug therapy, Leukemia, Myeloid, Acute therapy, Precursor Cell Lymphoblastic Leukemia-Lymphoma drug therapy, Precursor Cell Lymphoblastic Leukemia-Lymphoma therapy
Abstract

Background: The possibility of performing syngeneic hematopoietic stem cell transplantation is rare and there are concerns about the absence of a graft-versus-leukemia effect following such a strategy. We report the outcomes of a large series of adult patients who underwent syngeneic hematopoietic stem cell transplantation for acute myeloblastic leukemia or acute lymphoblastic leukemia., Design and Methods: The outcomes of all syngeneic transplants for acute myeloblastic or lymphoblastic leukemia reported to the European Group for Blood and Marrow Transplantation registry were analyzed; a study of prognostic factors was performed for those transplanted in first complete remission., Results: One hundred and sixty-two patients, 109 with acute myeloblastic leukemia and 53 with acute lymphoblastic leukemia, were identified; 116 were in first complete remission. Most of the patients did not receive prophylaxis against graft-versus-host disease. Nineteen patients developed acute graft-versus-host disease and only three patients developed chronic graft-versus-host disease. The median follow-up was 60 months. At 5 years the non-relapse mortality was 8 +/- 5%, the relapse incidence 49 +/- 8% and the leukemia-free survival 43 +/- 3%. The corresponding figures for patients in first complete remission were 7 +/- 2%, 40 +/- 4% and 53 +/- 5% at 5 years. Analysis of patients in first complete remission showed that the number of courses of chemotherapy required to induce first complete remission was the main risk factor: the leukemia-free survival at 5 years was 66 +/- 6% when first complete remission was reached after one induction course of chemotherapy and was only 20 +/- 9% when first complete remission was reached after at least two induction courses of chemotherapy (p = 0.0001); the relapse incidence was 30 +/- 6% and 54 +/- 10%, respectively (p = 0.007)., Conclusions: Outcomes were better for patients transplanted in first complete remission than in second complete remission or a more advanced phase of the disease. When a syngeneic donor is available for patients with high risk acute leukemia, allotransplantation should be performed as soon as the first complete remission has been achieved, ideally with one course of chemotherapy.

Published
2008
Full Text
View/download PDF

42. [Mesenchymal stem cells from human proximal femurs possess immunosuppressive activity].

Author

Zhang YZ, Fouillard L, Chapel A, Bensidhoum M, Mazurier C, Nasef A, Bouchet S, Lopez M, Thierry D, Gorin NC, and Da WM

Subjects
Adult, Aged, Bone Marrow Cells cytology, Cell Proliferation, Cells, Cultured, Coculture Techniques, Female, Humans, Male, Middle Aged, Femur cytology, Immune Tolerance, Lymphocytes cytology, Mesenchymal Stem Cells cytology, Mesenchymal Stem Cells physiology
Abstract

Objective: To evaluate whether mesenchymal stem cells (MSCs) obtained from human proximal femurs possess immunosuppressive effect so as to look for ideal bank of MSCs for clinical prophylaxis and treatment of graft versus host disease (GVHD)., Methods: Human marrows were collected from the proximal femurs of patients undergoing hip replacement to isolate MSCs. The puncture materials obtained from the iliac bone marrow of 12 healthy donors were used as controls. Peripheral blood lymphocytes (PBLs) were obtained from the peripheral blood of healthy persons. 1 x 10(5) PBLs were mixed with allogeneic PBLs radiated by 60 cobalt and put into the wells of a 96-well plate. MSCs of the concentrations of 1 x 10(5), 3 x 10(4), 1 x 10(4), and 3 x 10(3), were added into the culture fluid of the mixed PBLs to be co-cultivated for 5 days. 1 microCi/well [(3)H] TdR was added in the last 18 hours. The cells were collected and the counts per minute (cpm) was detected. 3 x 10(4) and 1 x 10(4) MSCs were put into the wells. When the MSCs adhered to the wall, a membrane with micropores was inserted value of 1 x 10(5) PBLs and radiated allo-PBLs were put onto the top of which. Five days after cultivation 1 microCi/well [(3)H] TdR was added and the cpm was tested. MSCs were cultured in RPMI-1640 culture fluid and then contacted MLR constructed by 1 x 10(5) PBLs and 1 x 10(5) allo-PBL directly or via Transwell membrane with micropores. Five days after the supernatant was collected. ELISA was used to detect the content of TGF-beta(1). 0.1 microg/ml, 1 microg/ml, or 10 microg/ml anti-human TGF-beta1 antibody was added to the co-cultivation system. Five days after [(3)H] TdR was added so as to test the value cpm., Results: 3 x 10(3) - 1 x 10(5) MSCs from proximal femurs inhibited the PBLs proliferation to 62 +/- 18% - 28 +/- 12% of maximal response, however, not significantly different from that observed in MSCs collected from bone marrow of healthy donors via iliac crest aspiration (58 +/- 12% - 27 +/- 6%, P > 0.05). When these cells were separated physically from MLR system via a membrane with micropores 0.2 microm in diameter, 3 x 10(4) and 1 x 10(4) cells still markedly suppressed the PBLs proliferation to 36 +/- 8% and 53 +/- 13% of maximal response. ELISA showed that TGF-beta1 was measured in the supernatants of MSCs, MSCs + MLR and MSCs + MLR in Transwell system, without significant differences among these experimental conditions. Furthermore, the presence of increasing amounts of neutralizing anti- TGF-beta1 antibody did not reverse the inhibitory effect., Conclusion: MSCs obtained from the proximal femurs possess immunosuppressive activity. A soluble factor/factors was/were involved in such effect, however, TGF-beta1 was not a candidate.

Published
2005

43. Autologous stem cell transplantation for systemic lupus erythematosus.

Author

Jayne D, Passweg J, Marmont A, Farge D, Zhao X, Arnold R, Hiepe F, Lisukov I, Musso M, Ou-Yang J, Marsh J, Wulffraat N, Besalduch J, Bingham SJ, Emery P, Brune M, Fassas A, Faulkner L, Ferster A, Fiehn C, Fouillard L, Geromin A, Greinix H, Rabusin M, Saccardi R, Schneider P, Zintl F, Gratwohl A, and Tyndall A

Subjects
Adolescent, Adult, Chi-Square Distribution, Child, Cohort Studies, Europe, Female, Humans, Lupus Erythematosus, Systemic mortality, Male, Middle Aged, Prognosis, Proportional Hazards Models, Registries, Risk Assessment, Severity of Illness Index, Statistics, Nonparametric, Stem Cell Transplantation adverse effects, Survival Analysis, Transplantation, Autologous, Treatment Outcome, Lupus Erythematosus, Systemic diagnosis, Lupus Erythematosus, Systemic therapy, Stem Cell Transplantation methods, Transplantation Conditioning methods
Abstract

Systemic lupus erythematosus (SLE) is responsive to treatment with immunosuppressives and steroids, but often pursues a relapsing or refractory course resulting in increasing incapacity and reduced survival. Autologous stem cell transplantation (ASCT) following immunoablative chemotherapy is a newer therapy for autoimmune disease of potential use in severe SLE. A retrospective registry survey was carried out by the European Blood and Marrow Transplant and European League Against Rheumatism (EBMT/EULAR) registry. Data was collected from 53 patients with SLE treated by ASCT in 23 centres. Disease duration before ASCT was 59 (2-155) months (median, range), 44 (83%) were female, and median age was 29 (9-52) years. At the time of ASCT a median of seven American College of Rheumatology (ACR) diagnostic criteria for SLE were present (range 2-10) and 33 (62%) had nephritis. Peripheral blood stem cells were mobilized with cyclophosphamide and granulocyte colony stimulating factor in 93% of cases. Ex vivo CD34 stem cell selection was performed in 42% of patients. Conditioning regimens employed cyclophosphamide in 84%, anti-thymocyte globulin in 76% and lymphoid irradiation in 22%. The mean duration of follow-up after ASCT was 26 (0-78) months. Remission of disease activity (SLEDAI < 3) was seen in 33/50 (66%; 95%CI 52-80) evaluable patients by six months, of which 10/31 (32%; 95%CI 15-50) subsequently relapsed after six (3-40) months. Relapse was associated with negative anti-double stranded DNA (anti-dsDNA) antibodies before ASCT (P = 0.007). There were 12 deaths after 1.5 (0-48) months, of which seven (12%; 95%CI 3-21) were related to the procedure. Mortality was associated with a longer disease course before ASCT (P = 0.036). In conclusion, this registry study demonstrates the efficacy of ASCT for remission induction of refractory SLE, although mortality appeared high. The safety of this procedure is likely to be improved by patient selection and choice of conditioning regimen. The return of disease activity in one-third of patients might be reduced by long-term immunosuppressive therapy post-ASCT.

Published
2004
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results